Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA closes Eprex investigation

Executive Summary

FDA closes investigation of J&J's Manati, Puerto Rico facility, without any findings, J&J says. The investigation was prompted by a "whistleblower" suit in which a former employee alleged the company pressured him to falsify documents relating to the manufacture of Eprex (epoetin alfa), marketed in U.S. as Procrit (1"The Pink Sheet" July 22, 2002, p. 11). The suit was dismissed by San Juan Federal District Court in June at plaintiff's request, J&J says. The dismissal precludes the employee from bringing claims again...

You may also be interested in...



J&J Eprex EU Label Changed; FDA Investigating Manufacturing Fraud

Johnson & Johnson is recommending intravenous administration of Eprex (epoetin alfa) over subcutaneous administration in chronic renal failure patients in order to decrease the incidence of pure red blood cell aplasia in a July 17 "Dear Doctor" letter to physicians in the EU

Washington State Ecology Mulls ‘Safer’ Definition While Exploring Phthalate Alternatives In Fragrances

Marissa Smith, senior regulatory toxicologist in the Washington Department of Ecology’s Hazardous Waste and Toxics Reduction program, discusses what’s next for the state’s inaugural Safer Products go-round. “How we define ‘safer’ is really going to be the lynchpin of this whole process,” she says.

COVID-19 Deter Class Actions? No. Plaintiffs' Attorneys Have Time For More Complaints? Yes.

Class action complaints filed in 2020 against food, dietary supplement and beverage firms should pass 2019’s total as COVID-19 has not slowed litigants but has given plaintiffs’ council more time out of court to shop for new cases.

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel